Sara Maestrini

Dr. Sara Maestrini

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2024 in RSC Advances
Verified
Journal Article
Open access
PDF file
VCVittorio Ciccone
Vittorio Ciccone
ADAurora Diotallevi
Aurora Diotallevi
MGMiriam Gómez-Benmansour
Miriam Gómez-Benmansour
SMSara Maestrini
Sara Maestrini
FMFabio Mantellini
Fabio Mantellini
Gianfranco FaviGianfranco Favi
Gianfranco Favi
A chemoselective one-pot synthesis of indole–pyrrole hybrids has been developed. The new hybrids were phenotypically screened for efficacy against L. infantum promastigotes. Compound 3d was the most active with IC50 = 9.6 μM and a selectivity index of 5.

19 May 2025 in Chemistry – A European Journal
Verified
Journal Article
Open access
ABAlessandro Buono
Alessandro Buono
ADAurora Diotallevi
Aurora Diotallevi
SMSara Maestrini
Sara Maestrini
MVMichele Verboni
Michele Verboni
PKPaula Kiuru
Paula Kiuru
Simone LucariniSimone Lucarini
Simone Lucarini
Leishmaniasis is a neglected tropical disease which presents significant global health challenges due to the lack of effective vaccines and the limitations of existing chemotherapeutics in view of their toxicity, resistance, and high costs. In this study, we realized a library of novel bisindole derivatives as potential antileishmanial agents through a rapid Suzuki‐Miyaura coupling reaction, utilizing NH2‐unprotected bromobisindole ethanamines and boronic acids. Optimization of reaction conditions allowed for the efficient and selective arylation of these substrates, with yields up to 93%. The compounds were screened for their activity against Leishmania infantum promastigotes. Among the tested bisindole derivatives, 3af (bearing a 4‐vinylphenyl moiety) demonstrated potent antileishmanial activity (IC50 = 1.1 µM) with a higher selectivity index (21.8) compared to the reference drug miltefosine (9.8). A significant activity was also retained against intracellular amastigotes. This study establishes a robust methodology for late‐stage functionalization of bisindoles, also highlighting these derivatives' potential as promising leads for antileishmanial drug development.

19 July 2024 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
SMSara Maestrini
Sara Maestrini
ADAurora Diotallevi
Aurora Diotallevi
LSLuca Santilli
Luca Santilli
BCBenedetta Canovari
Benedetta Canovari
COChiara Orlandi
Chiara Orlandi
LGLuca Galluzzi
Luca Galluzzi

3 March 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
SMSara Maestrini
Sara Maestrini
ADAurora Diotallevi
Aurora Diotallevi
SHSarah Hijazi
Sarah Hijazi
SHSara Habouria
Sara Habouria
EFemanuela frangipani
emanuela frangipani
LGLuca Galluzzi
Luca Galluzzi
Leishmania spp., the causative agents of leishmaniasis, pose significant global health threats, with visceral leishmaniasis being the most severe and fatal form. The increasing drug resistance in the treatment of leishmaniasis emphasizes the urgent need for novel therapeutic approaches. One promising strategy involves targeting essential cellular mechanisms such as nutrient acquisition, particularly iron, which is critical for energy metabolism and signal transduction. Leishmania spp. cannot synthesize heme de novo and rely on host-derived iron and heme for survival and pathogenicity. Gallium [Ga(III)] is an iron [Fe(III)]-mimetic molecule that has emerged as a promising antimicrobial agent, offering a novel approach to combat infections, mainly by replacing Fe(III) in redox enzymes thereby disrupting essential metabolic pathways and impairing microbial viability. In this study, the antiparasitic activity of Ga (III)-protoporphyrin IX (GaPPIX) was tested against Leishmania major and Leishmania infantum , both in promastigotes and intracellular amastigotes. Our results demonstrate that GaPPIX inhibits the viability of both species, specifically targeting the enzymatic activity of cytochrome c oxidase, with a higher sensitivity observed in L. major . The inhibitory effect is reversed by hemin, suggesting specificity for Leishmania heme-dependent cellular processes and a possible cytostatic action. Moreover, we found that GaPPIX can effectively synergize with miltefosine. This feature, coupled with its minimal toxicity toward human cells, makes GaPPIX a good candidate to be potentially developed as a novel anti- Leismania agent. IMPORTANCE: This study is significant as it addresses a critical challenge in leishmaniasis management, namely, the increasing incidence of drug resistance and toxicity, compounded by the scarcity of effective therapeutic options. We demonstrate that GaPPIX, a heme-mimetic compound, exhibits potent antiparasitic activity against both Leishmania major and Leishmania infantum , while displaying minimal cytotoxicity toward human cells, underscoring its potential as a safe and targeted therapeutic candidate. Importantly, the ability of GaPPIX to synergize with the first-line drug miltefosine highlights its translational relevance in combination therapies, which are essential for overcoming resistance and improving treatment efficacy. Collectively, these findings advance GaPPIX as a promising approach for the development of innovative therapeutics against a neglected but globally significant disease.

24 August 2026 in ACS Infectious Diseases
Verified
Journal Article
Open access
Gian Marco ElisiGian Marco Elisi
Gian Marco Elisi
AGAntonio Gkoutzamanis
Antonio Gkoutzamanis
SMSara Maestrini
Sara Maestrini
CECécile Exertier
Cécile Exertier
MEMichela Eleuteri
Michela Eleuteri
Simone LucariniSimone Lucarini
Simone Lucarini
The urgent need for new antileishmanial drugs persists due to resistance and toxicity associated with current treatments. Although bisindoles represent a promising chemotype, our first-generation 2,2′-di(indol-3-yl)ethanamines, inspired by a natural marine alkaloid, displayed significant cytotoxicity despite potent activity against L. infantum. To address this limitation, we designed and synthesized a second-generation series in which the indole bromine substituents were removed, and N-methylation was prioritized as a strategy to mitigate cytotoxicity. Compounds 1e, 2b, 2f, 3d, and 3e emerged as promising hits, exhibiting potent activity against L. infantum promastigotes (IC50 = 0.6–3 μM) and markedly improved selectivity indices (SI = 11–66) in THP-1 cells. These compounds retained efficacy in an in vitro infection model, with 1e, 2b, and 2f displaying IC50 values below 10 μM against intracellular amastigotes. A pharmacophore model derived from URB1483 and 2f was generated to explore plausible mechanisms of action underlying the antileishmanial activity, with trypanothione reductase (TR) selected as a possible biological target. While compound 2f showed only weak inhibition (IC50 = 71 μM), this could provide a starting point for the structure-based design of future antileishmanial agents. Preliminary ADME-related evaluations of 1e and 2f revealed improved aqueous solubility, alongside favorable chemical and metabolic stability specifically for 1e. Consequently, while 2f could be a new hit for a still underexploited target, compound 1e emerges as the most balanced lead candidate for future development of antileishmanial derivatives.

11 November 2026 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
Marcello CeccarelliMarcello Ceccarelli
Marcello Ceccarelli
SMSara Maestrini
Sara Maestrini
ADAurora Diotallevi
Aurora Diotallevi
GBGloria Buffi
Gloria Buffi
CMChiara Miosi
Chiara Miosi
LGLuca Galluzzi
Luca Galluzzi
Molecular diagnostic approaches, particularly qPCR-based assays targeting nuclear or kinetoplast DNA, have drastically improved the sensitivity of Leishmania detection. However, standard qPCR methods fail to directly differentiate closely related species, such as L. (L.) infantum and L. (L.) donovani , representing a critical limitation for accurate diagnosis and epidemiological surveillance. While whole-genome sequencing and multilocus microsatellite typing can resolve species and uncover L. (L.) infantum/L. (L.) donovani hybrids, both methods are costly and time-consuming. In this study, we developed a dual-target qPCR coupled with high-resolution melting (HRM) analysis to discriminate the Old World Leishmania species of medical interest, in particular L. (L.) infantum , L. (L.) donovani , and genotypes associated with putative L. (L.) infantum/L. (L.) donovani hybrids, directly from clinical specimens. The assays target specific polymorphisms within two metabolic genes: malic enzyme (ME) and nucleoside hydrolase (NH). The performance and discriminative power of this system were validated using a panel of reference strains, clinical isolates, and clinical samples of human and canine origin. The developed qPCR-HRM assays successfully differentiated L. (L.) infantum from L. (L.) donovani and identified L. (L.) infantum variants, including samples displaying putative L. (L.) infantum/L. (L.) donovani hybrid-like profiles. Importantly, the method demonstrated high analytical sensitivity (one parasite per reaction tube) and 82.7% typing rate when applied directly to clinical samples, allowing to discriminate among strains within the L. (L.) donovani complex bypassing parasite isolation. This dual-target qPCR-HRM approach provides a rapid and cost-effective screening tool for Old World Leishmania species identification and genotyping. By enabling direct analysis from clinical samples, this method holds strong potential to improve surveillance and epidemiological tracking of human and canine leishmaniasis. IMPORTANCE: This study provides an affordable and rapid method to distinguish closely related Leishmania parasites directly from clinical samples, without the need for parasite isolation or expensive genome sequencing. Accurate identification of these parasites is important because different species and strains can have distinct geographical distributions, transmission cycles, and animal reservoirs, making them essential to track for effective disease surveillance and control. By combining high sensitivity with the ability to identify species and variants within the L . ( L .) donovani complex in a single workflow, this method fills an important gap between routine diagnostic tests and advanced genomic approaches. Its rapidity and low cost make it suitable for use in diagnostic laboratories, particularly in settings where access to sequencing technologies is limited. Ultimately, this approach can strengthen disease surveillance, improve monitoring of parasite transmission, and support more effective public health and veterinary control strategies for leishmaniasis.